Lupin Ltd Receives EIR from US FDA for its Nagpur Injectable Facility

Global pharma major Lupin Limited has announced receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur, India. The EIR was issued following an inspection from September 8 to September 16, 2025, with a satisfactory Voluntary Action Indicated (VAI) classification. Lupin is committed to maintaining high standards of quality and compliance across its facilities, with a focus on enhancements to quality systems and operational excellence.